印度面临严重的抗微生物抗药性危机,感染率高,死亡率上升,引发了新的国家行动计划。 India faces a severe antimicrobial resistance crisis, with high infection rates and rising deaths, prompting a new national action plan.

抗微生物抗药性(AMR)日益成为全球健康威胁, 据专家说,印度面临着世界最高负担之一。 Antimicrobial resistance (AMR) is a growing global health threat, with India facing one of the world’s highest burdens, according to experts. 数据显示,印度三分之一的细菌感染者对普通抗生素有抗药性,远远超过全球平均水平,80%以上的患者携带多抗药性生物体。 Data shows one in three bacterial infections in India are resistant to common antibiotics, far exceeding the global average, with over 80% of patients carrying multidrug-resistant organisms. E. Coli、Klebsiella和Acinetobacter等关键病原体表现出惊人的抗药性,对卡巴匹宁和同化剂等最后抗药性的抗药性正在上升。 Key pathogens like E. coli, Klebsiella, and Acinetobacter show alarming resistance, and resistance to last-resort drugs like carbapenems and colistin is rising. 2019年,印度记录了大约267 000例与甲型MR有关的死亡。 In 2019, India recorded an estimated 267,000 AMR-related deaths. 政府推出了新的《国家行动计划》(2025-2029年),强调 " 一个健康 " 方针、更好的监测和负责任的抗生素使用。 The government has launched a new National Action Plan (2025–2029) emphasizing a One Health approach, better surveillance, and responsible antibiotic use. 专家们警告说,如果不采取紧急行动,例行感染就可能变得无法治疗。 Experts warn that without urgent action, routine infections could become untreatable.